Nucleoside analogs are structurally, metabolically, and pharmacodynamically related agents that nevertheless have diverse biological actions and therapeutic consequences. This class of agents affects the structural integrity of DNA, generally after incorporation during replication or DNA excision repair synthesis, leading to stalled replication forks and chain termination. The DNA damage sensors ATM, ATR and DNA-PK recognize these events. These and other protein kinases activate checkpoint pathways that arrest cell cycle progression, and also signal for DNA repair. In addition, if these survival mechanisms are overwhelmed by the damage caused, a third function of these sensors is to activate signaling pathways that initiate apoptotic processes. A review of the spectrum of responses that are activated by clinically relevant nucleoside analogs begins to provide a mechanistic basis for diverse outcomes in cell viability. Such information, when coupled with an understanding of the intrinsic apoptotic potential of a tumor cell type may provide a rational basis for the design of therapeutic strategies.
Introduction
Nucleoside analogs comprise a major class of chemotherapeutic agents for the treatment of cancer and viral diseases. The effectiveness of these agents as antitumor drugs was established in the 1960s with the nucleobase antimetabolites 5-fluorouracil (Heidelberger et al., 1983) and the thiopurines (Elion, 1989) . Subsequently, nucleosides, which are frequently altered in the carbohydrate moiety, became the focus for the development of nucleic acid analogs. Most efforts were directed at the constituents and their configuration about the 2 0 -carbon, as this is a site at which DNA metabolizing enzymes are quite discriminating. The recognition that the pyrimidine nucleoside analog arabinosylcytosine (ara-C), had activity in acute myelogenous leukemia generated enthusiasm for the investigation of congeners that might have a broader spectrum of activity (Grant, 1988) . This was achieved with the development of gemcitabine, another carbohydratemodified analog of deoxycytidine , which is effective against a variety of solid tumors (Storniolo et al., 1999) , and may also have therapeutic value in hematological malignancies (Santoro et al., 2000; Zinzani et al., 2000) . In parallel with the emergence of gemcitabine came the investigations that established that the family of purine nucleoside analogs, fludarabine, cladribine, and pentostatin, has major activity in indolent B-cell malignancies. The mechanisms of action and the clinical activities of all these agents have recently been reviewed in depth (Cheson et al., 1997; Saven et al., 1998; Grem et al., 1999; Keating, 1999a and b; Dearden et al., 2000; Johnson, 2000) .
One of the remarkable features that remains unexplained about nucleobase and nucleoside analogs, known collectively as nucleic acid antagonists, is how drugs with such similar structural features, which share metabolic pathways and elements of their mechanisms of action, show such diversity in their clinical activities. It remains for ongoing investigations to provide clues to this fascinating puzzle. Quite possibly, part of the answer to this mystery may reside in how the actions of the analogs are sensed by cells, the diversity of signals for cell death that are initiated, and the varying abilities of normal and tumor cells to resist the activation of apoptosis. This article will briefly address the actions of the major nucleoside analogs in clinical use for cancer therapy. Subsequently, we will review the current state of knowledge of the pathways that are activated as signaling for cell death is initiated by various pharmacodynamics effects. In addition, although space constraints do not permit detailed discussion herein, the reader should be aware of a series of newer nucleoside antagonists that exhibit still other mechanisms of action (Plunkett and Gandhi, 2001) , which are presently being evaluated in the initial stages of clinical trials (Faderl et al., 2002) .
Actions of nucleic acid antagonists
Most nucleic acid antagonists exert their cytotoxic effects by interfering with DNA replication. Although a variety of metabolic pathways are utilized to achieve pharmacodynamic effects, the end results of these actions show commonalities among this class of agents in the means of blocking DNA synthesis. Thus, review of the mechanisms of action will show only a few differences in the qualitative end points. However, it is likely that the quantitative nature of these actions does vary, in some cases being influenced by other effects of the same nucleotide. In addition, some analogs have several actions that can be considered to be significant threats to viability, thereby further complicating an evaluation of the events that trigger an apoptotic response. These actions and the potential biological consequences are summarized in Table 1 .
The nucleobases, 5-fluorouracil and the thiopurines, are among the most venerable agents in cancer therapy (Figure 1 ). In what is thought to be its major action, 5-fluorouracil is anabolized to the respective deoxynucleoside monophosphate, FdUMP, which competes with the normal metabolite, dUMP, as a potent inhibitor of thymidylate synthase (Pinedo and Peters, 1988; Parker and Cheng, 1990) . This enzyme governs the de novo synthesis of thymidylate, and its inhibition results in a specific depletion of dTTP. This is associated with an inhibition of DNA replication that is characterized at the molecular level as stalled replication forks. FdUMP may be further anabolized to the triphosphate, FdUTP, which serves as an alternative substrate for dTTP in DNA replication. Once incorporated into DNA, this is a substrate for the base repair enzyme, uracil glycosylase. If multiple analog residues are incorporated in close proximity, the attempts to remove them may result in DNA fragmentation (Ingraham et al., 1982) . The ribonucleoside triphosphate of 5-fluorouracil, FUTP, may be incorporated into RNA, and affect the function of transcripts (Longley et al., 2003) .
Each of the thiopurines, 6-mercaptopurine and 6-thioguanine, are anabolized to the dGTP analog, 6-thiodGTP, which is an efficient substrate for DNA polymerases (Fink D et al., 1998; Massey et al., 2001) . However, the thiol group causes alterations in hydrogen bonding that are recognized by the mismatch repair system. Attempts to remove the closely adjacent misincorporated analogs can lead to discontinuities in the DNA, which presumably attract sensors that signal for cell death.
The first nucleoside analog containing an alteration in the carbohydrate moiety, ara-C, is widely used for the treatment of acute leukemias (Johnson, 2001) (Figure 2) . The nucleoside is phosphorylated to its triphosphate, ara-CTP, which competes with dCTP as a substrate for incorporation into DNA (Townsend and Cheng, 1987; Ohno et al., 1988) . Once incorporated, the analog can serve as an inefficient substrate for extension, which would likely simulate a stalled replication fork. Alternatively, the tandem incorporation of a second ara-C residue would almost certainly cause chain termination.
While the analog at the 3 0 -terminus can be excised, this proceeds at a rate that is considerably less than a normal nucleotide .
A second deoxycytidine nucleoside analog, gemcitabine, has clinical activity in a large spectrum of solid tumors and some hematological malignancies (Storniolo et al., 1999; Tempero et al. 2003) . As with ara-C, gemcitabine accumulates in cells mainly as the triphosphate dFdCTP, and is a substrate for incorporation into DNA (Figure 2 ). It appears to be more efficiently extended than ara-C, although tandem incorporation mimics chain termination in experimental systems . It is a poor substrate for excision from the 3 0 -terminus of DNA. The diphosphate of gemcitabine dFdCDP is a mechanismbased inhibitor of ribonucleotide reductase, which appears to irreversibly inactivate this key enzyme leading to a decrease in dNTP pools (Heinemann et al., 1990) . As a result, a decrease in the cellular concentration of dCTP is observed. The change in the dFdCTP : dCTP value would favor the incorporation into DNA, a process known as self-potentiation (Heinemann et al., 1992) . It is possible that the decreased availability of dNTPs may temper this effect by slowing of the overall replication process.
The inhibitory actions against DNA replication of fludarabine, an arabinosyl nucleoside analog with clinical activity in indolent malignancies as well as against acute leukemias (Keating, 1997) , are similar to those of ara-C (Huang et al., 1990 (Figure 3) . Also, the triphosphate appears to act at a regulatory site of ribonucleotide reductase to inhibit the enzyme reversibly, lowering cellular dNTP pools Parker et al., 1988) . However, unlike ara-C, once the analog triphosphate is incorporated in DNA, attempts to excise the analog result in inactivation of both the excision and polymerizing activities of DNA polymerase (Kamiya et al., 1996) . In addition, when the fludarabine residue is at the 3 0 -terminus, the DNA cannot be ligated (Yang et al., 1992) . Thus, it is likely that the signals for apoptosis in growing cells are largely due to the actions of fludarabine as a chain terminator. The cytotoxic actions of fludarabine are not so clear in quiescent cells, in which the incorporation of the nucleotide analog into DNA is barely detectable. Unlike other arabinosyl nucleosides, fludarabine is also incorporated into RNA, an action that can terminate transcription Huang et al., 2000) . This is associated with the decrease in antiapoptotic proteins with intrinsically short half-lives, such as Mcl-1 and XIAP, an action that may curtail the survival capacity of CLL cells (Kitada et al., 1998) .
A second purine nucleoside analog, cladribine, is active in indolent lymphocytic malignancies (Goodman et al., 2003) and pediatric acute myelogenous leukemia (Crews et al., 2002) (Figure 3 ). It is modified only on the nucleobase and contains a normal 2 0 -deoxyribose carbohydrate moiety. Accordingly, the triphosphate readily incorporated into DNA, and thereafter is also a fair substrate for extension (Hentosh et al., 1990) . As with fludarabine, this process may be facilitated by the inhibitory activity of the triphosphate against ribonucleotide reductase, which seems to be similar in mechanism, but more potent than that of fludarabine triphosphate (Parker et al., 1988) . Thus, cladribine may exhibit the properties of an agent that stalls replication forks.
Pentostatin (deoxycoformycin) is a natural product, active in indolent leukemias (Johnson, 2001) , that is an extremely potent inhibitor of adenosine deaminase (Agarwal, 1982) (Figure 3 ). This action blocks the metabolic clearance of deoxyadenosine that arises from the normal turnover of cells, particularly those of hematopoietic processes. As a result, deoxyadenosine triphosphate accumulates, particularly in cells with high activities of deoxycytidine kinase (Plunkett et al., 1982; Seto et al., 1986) . This imbalance of dNTP pools can directly affect DNA replication, and may also block the production of other dNTPs as dATP is a strong negative allosteric inhibitor of ribonucleotide reductase (Bianchi et al., 1992) . These actions may stall replication forks and result in misinserted deoxynucleotides.
As an ancillary consideration, fludarabine and cladribine are each anabolized to triphosphate analogs of dATP, and pentostatin causes the accumulation of dATP. Importantly, dATP has been identified as a cofactor in the apoptosome complex in the intrinsic pathway of apoptosis (Li et al., 1997) . This has given rise to a hypothesis that these nucleotides may act directly to influence the activity of the apoptosome complex, an action that may have particular significance for the actions of these agents in cells that are not replicating their DNA (Leoni et al., 1998; Genini et al., 2000a, b) .
Finally, it is clear that some nucleoside analogs can have major effects on the epigenetic regulation of gene transcription. This is the case for both 5-aza-cytidine and its 2 0 -deoxy congener (5-aza-2 0 -deoxycytidine, decitabine), which is in widespread preclinical use (Haaf, 1995) triphosphate of these compounds is readily incorporated into DNA. Because of the nitrogen substitution for the 5-carbon in the cytosine moiety, this molecule cannot be methylated by the DNA methyltransferase enzymes. When incorporated into CpG islands in promoter regions of genes that are normally transcriptionally inactive due to methylation, the corresponding genes are substrates for transcription (Jones and Baylin, 2002) . As expression of both caspase-8 and caspase-1 is activated by treatment of cells with 5-aza-deoxycytidine, this action of the analog may affect the susceptibility of cells to activate apoptosis. A separate mechanism by which incorporation of 5-aza-cytidine into DNA affects cells relates to the inherent instability of the substituted ring. As a 5-aza-cytosine aglycone is unstable and undergoes ring opening in an aqueous environment, it is likely that this also occurs after incorporation. If so, this may attract base excision repair enzymes with biochemical sequelae similar to those that occur when 5-fluorouracil becomes incorporated into DNA or after base oxidation.
The chemistry of the actual lesions caused by nucleic acid antagonists is not clear. It is well known that cells have repair mechanisms that probably evolved to facilitate the removal of misinserted and damaged nucleotides. Thus, the 3 0 -5 0 exonucleases intrinsic to DNA polymerases used for replication, or proofreading enzymes associated with some polymerases, could be considered the first line of defense. Some nucleotide analogs may be substrates for these activities, but others appear to be resistant to this form of repair. Presumably, the reinitiation of replication forks stalled due to the decreased dNTP pools may be facilitated by mechanisms that are well defined in bacteria, and are being investigated in eukaryotes (Cox et al., 2000; Goodman, 2000) . On the other hand, failure to remove a chain-terminating nucleotide may be recognized as a single-strand break or it could be processed into a double-strand break. Removal by base excision repair mechanisms of nucleobase analogs that have been incorporated and then extended in the nascent DNA is another potential means of repair. Also, recognition of analogs with hydrogen bonding abnormalities by the mismatch repair system may help the cell avert potentially lethal damage. Each of these repair processes may be viewed as a potential mechanism of resistance, particularly when it is highly expressed or the damage is marginal. It is intuitive that the sensitivity of repair mechanisms to the actions of nucleic acid antagonists would be greater than the mechanisms that signal for cell death. However, it is also reasonable to suppose that given the failure of repair mechanisms to correct the function of these processes, the recognition of such events by sensor molecules will serve to activate the apoptotic pathways. Understanding the mechanisms of tolerance of cells to actions of nucleic acid antagonists, and identifying the biochemical basis for exceeding the threshold sufficient to activate apoptotic pathways remain challenging goals.
Sensors of DNA damage in replicating cells
The earliest manifestation of the apoptotic response to nucleic acid antagonists would be the damage they cause to DNA. The most prevalent forms of DNA damage caused by nucleic acid antagonists are those that result from stalling of replication forks, frank termination of nascent DNA synthesis, and the immediate results of the manner in which cells attempt to recover from such insults. What then are the mechanisms by which cells recognize this damage to transduce it into an apoptotic response? It appears that when replication is blocked, replication intermediates containing short singlestranded regions are formed, which likely activate cell cycle checkpoint mechanisms. In yeast, Rad 53 and the ATR homolog Mec1 appear to control the stability of the stalled fork (Cha and Kleckner, 2002; Sogo et al., 2002) . In higher eukaryotes, both ATR and Chk1 have a role in maintaining the potential functionality of stalled replication forks (Brown and Baltimore, 2003; Zachos et al., 2003) . Although the exact nature of the damage caused by nucleoside analogs in stalling replication forks is poorly understood, it follows that cellular responses to these agents are likely to overlap those elicited by drugs such as hydroxyurea (HU) that also cause replication forks to stall by limiting dNTP production. Also, crystallographic studies have demonstrated that incorporation of ara-C into DNA causes localized alterations in the DNA duplex (Schweitzer et al., 1994) and stabilizes covalent topoisomerase I-DNA complexes, thus converting the enzyme into a cellular poison (Pourquier et al., 2000; Chrencik et al., 2003) . This suggests that cellular responses to nucleoside analogs are also likely to overlap those elicited by the camptothecin family of topoisomerase I active agents. 
Cell cycle arrest
In leukemia cells, the cellular responses are determined by the amount of fludarabine nucleotide incorporated; levels greater than 10 5 molecules per genome induce apoptosis (Sampath and Plunkett, 2000) , whereas less than that amount induce arrest in the S phase (Sampath et al., 2002) . Activation of the S phase DNA damage checkpoint may form the basis for a resistance mechanism that circumvents nucleoside analog-induced toxicity. Therefore, an understanding of the molecular mechanisms that regulate the S phase checkpoint may offer insights into therapeutic strategies aimed at dysregulation of the checkpoint, thereby resulting in cell death ( Figure 5 ).
Replication blocks, in general, elicit checkpoint responses in the S phase. For instance, HU and aphidicolin inhibit DNA replication by depleting deoxynucleotide pools and inhibiting DNA polymerases, respectively, and activate the S phase checkpoint. Fludarabine, ara-C, gemcitabine (Shi et al., 2001; Zhao and Piwnica-Worms, 2001; Sampath et al., 2002) and other S phase acting agents such as topoisomerse I poisons (Cliby et al., 2002; Wang et al., 2002) and UV (Heffernan et al., 2002 ) also activate an intra-S checkpoint. Therefore, it seems likely that a common complement of sensor molecules would function to detect replication stress/damage caused by a diverse set of S phase-directed agents to activate the intra-S checkpoint. It is thought that the proteins that respond earliest to HU-or UV-mediated replication stress are the DNA clamp loading protein Rad17, and the heterotrimeric clamp Rad9-Hus1-Rad1 (9-1-1 complex) (Roos-Mattjus et al., 2002 . Rad17 preferentially bound to nicked DNA and recruited the 9-1-1 complex (Bermudez et al., 2003) . The 9-1-1 complex then enabled ATR to recognize its substrates (Zou et al., 2002) . ATM, ATR, and DNA-dependent protein kinase (DNA-PK) are serine/threonine kinases that represent a second set of DNA damage sensors that respond to UV, HU, and camptothecin-mediated replication stress. While the role of ATM and DNA-PK in regulating the nucleoside analog-initiated S phase checkpoint remains to be elucidated, evidence suggests that ATR may play a prominent role in sensing unreplicated DNA (Zhao and Piwnica-Worms, 2001; Cliby et al., 2002; Heffernan et al., 2002; Zou et al., 2002) . For instance, cells that lack ATR are hypersensitive to HU, UV, and topoisomerase poisons (Zhao and Piwnica-Worms, 2001; Cliby et al., 2002; Heffernan et al., 2002; Zou et al., 2002) . Activated ATR recruits the H2AX protein and its signaling partners (Ward and Chen, 2001; Furuta et al., 2003) . Phospho-H2AX foci form within minutes following DNA damage and colocalize with the checkpoint proteins of the Mre11, Rad50, and Nbs1 (MRN) complex.
ATR also phosphorylates the cell cycle checkpoint kinase Chk1 on Ser 317 and Ser 345 to cause its activation to enact cell cycle arrest in both the S and G2 phases (Lopez-Girona et al., 2001; Zhao and PiwnicaWorms, 2001; Capasso et al., 2002) . Disruption of ATR function inhibited the phosphorylation of Chk1 and abrogated the Chk1-dependent S phase checkpoint (Zhao and Piwnica-Worms, 2001; Cliby et al., 2002; Heffernan et al., 2002) . A role for ATR in detecting ara-C and other related nucleoside analog-induced DNA damage is suggested by a number of lines of evidence. For instance, cells exposed to caffeine, an inhibitor of ATM and ATR, can reverse the S phase arrest induced by ara-C (Sugimoto et al., 2000) . Leukemia cells respond to fludarabine by activating an intra-S phase checkpoint consisting of a hierarchical regulatory cascade through activated Chk1. This caused the inhibition of Cdc25A phosphatase with the consequent accumulation of Tyr-15-phosphorylated, and thus inactive, Cdk2 kinase, resulting in S-phase arrest (Sampath et al., 2002) .
In an analogous response to DNA damage, the nucleoside analog 2 0 -cyano-arabino-deoxycytidine is incorporated during DNA replication. However, this analog undergoes a beta elimination process that results in a single-strand break upon further polymerization. Although cells are able to continue their transit through S phase, they become arrested in G2, apparently because strand breaks were recognized, and the G2 checkpoint enacted by Chk1 . Such G2 arrest is associated with an accumulation of the Tyr-15-phosphorylated form of Cdk1, which is dependent upon activation of Chk1, which inhibits Cdc25C, and the consequent accumulation of inactive Tyr-15-phosphorylated Cdk1 (Liu et al., 2000; Zhou and Elledge, 2000) .
It may be that the ability of nucleoside analogs to trigger a Chk1-dependent cell cycle arrest Wang et al., 2002; Yin et al., 2002) can be therapeutically exploited to maximize cytotoxicity in combination with cell cycle checkpoint dysregulators ( Figure 5 ). In experimental systems, pharmacological inhibition of Chk1 using 7-hydroxystaurosporine (UCN-01) in nucleoside analogarrested cells resulted in a rapid abrogation of the S phase checkpoint and activated apoptosis in the Sphase population (Shi et al., 2001; Eastman et al., 2002; Sampath et al. 2002) . Further, the action of UCN-01 in potentiating the toxicity of ara-C and other S phase DNA-damaging agents was independent of p53 status (Shao et al., 1997; Sugiyama et al., 2000; Eastman et al., 2002; Kohn et al., 2002) . In addition to inhibiting Chk1, UCN-01 appears to inhibit Pdk1 (Sato et al., 2002; Komander et al., 2003) . As Akt is a substrate of Pdk1, such an action may affect the survival of cells that depend on the PI-3 kinase/Akt pathway for viability and growth.
Signals for cell death: sensors and transducers
The signals generated by genotoxins are likely to be sensed by one or more DNA damage sensors (Durocher and Jackson, 2001 ), but transduced by multiple, independent pathways that ultimately generate proapoptotic signals for cell death ( Figure 6 ). One possibility for a sensor molecule is the DNA-PK in complex with the Ku subunits. The DNA-PK/Ku complex is known to recognize DNA strand breaks, and thus becomes activated as a kinase that regulates the activity of a number of proteins that interact with DNA such as p53, a well-known transducer of genotoxic stress. DNA-PK is known to phosphorylate p53 on Ser15 and Ser37 (Kim et al., 1999) . After cells were exposed to cytotoxic levels of gemcitabine, DNA-PK formed a protein complex with p53 that preferentially bound to nucleoside analogcontaining DNA (Achanta et al., 2001) . This event appeared to trigger the kinase activity of DNA-PK, which then phosphorylated and stabilized p53. While it is well known that both ATM and ATR regulate the activity of p53 by phosphorylating it on several serine residues (Kastan et al., 2000; Hirao et al., 2002) , the role that these kinases play in activating p53 subsequent to nucleoside analog-induced damage remains to be elucidated. Activated p53 may initiate apoptosis by transcribing proapoptotic proteins (Miyashita and Reed, 1995; Oda et al., 2000) , triggering signaling pathways that culminate in apoptosis. DNA-PK as well as ATM also phosphorylate and regulate the activity of c-abl, a nonreceptor tyrosine kinase that is active in a variety of signaling pathways in the cellular responses to nucleoside analogs. Cells deficient in DNA-PK or ATM were inhibited in their ability to activate c-abl in response to IR Shafman et al., 1997) , but it is unknown whether activation of c-abl in response to nucleoside analogs has a similar dependence on DNA-PK or ATM. Once activated, c-abl generates proapoptotic signals utilizing multiple pathways Yuan et al., 1997; Raina et al., 2002) (Figure 6 ). One downstream effector of c-abl is the c-jun-N-terminal kinase (JNK) that is required for the translation of nucleotide analog-induced DNA damage into cell death Sampath and Plunkett, 2000) . Inhibition of JNK activity conferred resistance to nucleoside analogs (Sampath and Plunkett, 2000; Raina et al., 2002) . Similarly, inhibition of JNK activity by stable expression of dominant inactive forms of the nuclear protein tyrosine kinase Lyn abrogated the apoptotic response of cells to nucleoside analogs (Yuan et al., 1995; Yoshida et al., 2000) . Another downstream effector of c-abl is the Rad-9 protein that interacts with Bcl-xL and Bcl-2 to promote apoptosis (Komatsu et al., 2000; Yoshida et al., 2002) . Thus, it appears that multiple upstream sensor proteins activate signals that converge to activate apoptotic pathways at the level of JNK or p53 that then regulate the mitochondrial apoptotic machinery.
Intrinsic pathway leading to cell death
The intrinsic pathway of apoptosis triggered by DNA damage caused by nucleoside analogs results in mitochondrial-dependent activation of executioner caspases, which leads to the characteristic apoptotic phenotype. (Gunji et al., 1991; Ibrado et al., 1996; Datta et al., 2000; Shi et al., 2001) . Caspase activation occurs through the release of apoptogenic factors from the mitochondria, including cytochrome c and Smac/DIABLO (Budihardjo et al., 1999; Yin, 2000) . Released cytochrome c allows the formation of a high-molecular-weight complex, the apoptosome, which consists of the adapter protein Apaf-1, dATP, and procaspase-9. The latter is activated following recruitment into the apoptosome (Li et al., 1997; Zou et al., 1997) and then cleaves and activates the effector caspases, such as caspase-3 and caspase-7, which execute the death program.
Ara-C-mediated JNK signaling can directly regulate the intrinsic pathway for apoptosis by translocating to Raina et al., 2002) or by promoting the release of SMAC into the cytosol (Chauhan et al., 2003) . JNK, as well as DNA-PK, can also indirectly regulate the mitochondrial apoptosome by its ability to phosphorylate p53 and stabilize it (Buschmann et al., 2001 ). It appears that p53 signals to the mitochondria through more than one of the proapoptotic Bcl-2 family proteins. Accordingly, p53 response elements were found in the promoters of the proapoptotic protein, Bax (Miyashita and Reed, 1995) , and the BH3-only proteins Noxa (Oda et al., 2000) and PUMA (Yu et al., 2003) , which are upregulated during p53-induced cell death and activate the mitochondrial apoptotic pathway. While the requirement for c-abl and JNK in mediating nucleoside analog-induced apoptosis is clear, the importance of p53 in these apoptotic processes is likely to be cell-type specific, because cells with deficient p53 function are able to die by apoptosis in response to nucleoside analogs (Huang and Plunkett, 1995; Feng et al., 2000) . The pro-and antiapoptotic Bcl-2 family proteins regulate the intrinsic pathway by inducing or preventing the release of apoptogenic factors, such as cytochrome c or Smac/DIABLO, from the mitochondrial intermembrane space into the cytosol (Kluck et al., 1997; Yang et al., 1997) . In response to nucleoside analogs, the Bcl-2 family of proteins regulate this intrinsic pathway of caspase activation at multiple levels (Bullock et al., 1996) . For instance, CLL cells exposed to fludarabine induced conformational changes in the proapoptotic Bax and Bak and translocation to the mitochondria as an early event in the induction of apoptosis (Bellosillo et al., 2002; Dewson et al., 2003) Conversely, high levels of the antiapoptotic protein Bcl-2 and Bcl-2-related family members confer resistance to nucleoside analogs both in cell lines (Miyashita and Reed, 1993; Bullock et al., 1996; Kim et al., 1997) and primary AML samples (Keith et al., 1995; Konopleva et al., 2000 Konopleva et al., , 2002a . Methylation of APAF-1 conferred resistance to cytochrome c-dependent apoptosis in leukemia cells that was reversible by exposure to 5-azacytidine (Fu et al., 2003) . In contrast, survivin and XIAP members of the 'inhibitors of apoptosis' that interfere with activation of the executioner caspases did not affect the survival of primary AML cells in response to ara-C (Carter et al., 2003) .
Extrinsic pathway leading to cell death
Although nucleic acid antagonist-induced apoptosis clearly proceeds through the effector caspases Datta et al., 2000; Shi et al., 2001) , their mechanism of activation, whether through intrinsic mitochondrial-mediated events or through the recruitment of death receptor-mediated extrinsic apoptotic pathways, appears to depend on the experimental context. It was shown that arabinosylnucleoside-induced apoptosis could proceed through an upregulation of Fas (Rodriguez et al., 2003) and TRAIL receptor 2/ DR5 in a p53-independent fashion (Wen et al., 2000) ( Figure 7 ). Methylation-dependent inhibition of Fas has been associated with resistance to Fas-mediated cell death. Consequently, exposure to 5-azacytidine restored the sensitivity of colon cancer cells to Fas-induced apoptosis (Petak et al., 2003) . Other such as 5-fluorouracil upregulate Fas expression in a p53-dependent manner, resulting in Fas-mediated killing of colon carcinoma cells (Petak et al., 2000; Petak and Houghton, 2001 ). Once induced, the death receptors induce cleavage of caspase-8 and caspase-3 directly leading to cell death. The extrinsic and intrinsic pathways are intimately related (Figure 7) . Activation of caspase-8 leads to the cleavage of Bid, which translocates into the mitochondria and regulates the release of cytochrome c from mitochondria (Budihardjo et al., 1999; Yin, 2000) . Methylation-dependent inhibition of caspase-8, the apical caspase in death receptor-mediated death, correlates with resistance to TRAIL-and Fas-induced death. Accordingly, 5-azacytidine can restore death in response to these agents (Grotzer et al., 2000; Eggert et al., 2001; Fulda et al., 2001) . Loss of the function of executioner caspases such as caspase-8 or caspase-1 can occur due to methylation of their promoters and confers resistance to chemotherapy-induced cell death by inhibiting the intrinsic pathway of cell death (Fulda et al., 2001; Harada et al., 2002) or enhances the oncogenic potential of the tumors that harbor such mutations (Ueki et al., 2001) . Accordingly, recovery of caspase-8 and caspase-1 function by treatment with nucleoside analog 5-aza-2 0 -deoxycytidine restored the ability of these cells to undergo drug-induced apoptosis (Fulda et al., 2001; Ueki et al., 2001; Zhu et al., 2001) .
Actions of nucleoside analogs in quiescent cells
In the early 1970s, Giblett and her colleagues described inherited immunodeficiency syndromes associated with (Giblett et al., 1972) and purine nucleoside phosphorylase (Giblett et al., 1975) . These conditions were accompanied by the accumulation, in plasma, of deoxyadenosine and deoxyguanosine, respectively (Cohen et al., 1976) . This apparent selective toxicity to lymphocytes was characterized by the accumulation of the respective deoxynucleotide triphosphates, dATP and dGTP (Cohen et al., 1978a, b; Chan, 1978) . Carson and Kaye (1978) subsequently reasoned that the lymphocytoxic actions of normal deoxynucleotides produced to excess in the absence of catabolic enzymes might be mimicked by purine nucleoside analogs that were not substrates for these enzymes. Subsequent studies by this group demonstrated the potent cytotoxic activity of 2-chlorodeoxyadenosine (cladribine) and of deoxyadenosine to nondividing human lymphocytes, which was associated with a decrease in both NAD and ATP levels as poly(ADPribose) accumulated (Seto et al., , 1986 . This led to the hypothesis that dATP and CldATP interfered with ongoing DNA repair processes, resulting in a timedependent increase in DNA breaks that ultimately resulted in cell death in normal and CLL lymphocytes that was later characterized as apoptosis (Carson et al., 1988) . These observations also provided a rationale for the design of combinations of cladribine and DNAdamaging agents in clinical trials.
While the molecular mechanism for the killing of quiescent lymphocytes with dATP and its analogs was initially obscure, the elucidation of the action of dATP in the activation of caspase-3 by the apoptosome complex of the intrinsic pathway of apoptosis provided a possible explanation (Li et al., 1997) . The structural resemblance of CldATP and F-ara-ATP to dATP suggested that these analog nucleoside triphosphates might participate either in place of or in addition to dATP. This was investigated in a cell-free assay system that, using extracts from normal and malignant lymphocytes, demonstrated that these adenine nucleotides and others could substitute for dATP in caspase-3 activation (Leoni et al., 1998; Genini et al., 2000a) . The actions of cladribine and a related adenine nucleoside analog, clofarabine (Plunkett and Gandhi, 2001 ), appeared to be more directly related to actions on the mitochondria than did those of fludarabine (Genini et al., 2000b) . Thus, the direct actions of purine nucleotide analogs on the apoptotic machinery may contribute to the activity of this class of compounds. Additional studies are needed to clarify the reasons for differences among the drugs.
DNA repair as a target for nucleoside analogs in quiescent cells
By the nature of their actions as DNA synthesis inhibitors, nucleoside analogs are effective in killing cycling cells. However, this requirement for incorporation into DNA potentially limits their actions in cells that do not have ongoing DNA synthesis. In quiescent cells, the metabolites of nucleoside analogs are likely to lack the opportunity to exert their DNA-directed actions. Initiating DNA excision repair processes allows nucleoside analogs to be incorporated into the repair patches by DNA polymerases during the resynthesis step. Following its incorporation, ara-C inhibited UVinitiated DNA repair in quiescent human fibroblasts (Kufe et al., 1984; Snyder et al., 1984) .
As the incorporated fludarabine nucleotide appears to terminate DNA synthesis and is resistant to removal, it was chosen as an inhibitor of the resynthesis steps in excision repair processes to evaluate the biological effects of this action. Quiescent human lymphocytes were preincubated with a minimally toxic concentration of fludarabine for 2 h prior to irradiation to permit the build-up of F-ara-ATP. Subsequently, irradiation with low levels of UV (2 J/m 2 ) activated nucleotide excision repair that incorporated the nucleotide analog into repair patches (Sandoval et al., 1996; Rao and Plunkett, 2003) . This resulted in significantly greater than additive cell killing by apoptosis. Blocking the incorporation step using a high concentration of the DNA polymeraseinhibitor aphidicolin abrogated cell death in irradiated lymphocytes, demonstrating that inhibition of the repair step was insufficient to initiate cell death. Rather, as aphidicolin blocked fludarabine nucleotide incorporation into repairing DNA and this spared cell death, this experiment demonstrated the importance of incorporation of the analog to initiating apoptosis. In addition, combinations of fludarabine with the alkylating agent cyclophosphamide in primary CLL lymphocytes also blocked repair, as indicated by comet assay, and triggered increased cytotoxicity over the single agents (Yamauchi et al., 2001) . Extended to clinical evaluation, the combination of fludarabine and cyclophosphamide generated clinical responses in patients with relapsed CLL who had previously failed to respond to regimens containing these agents separately (O'Brien et al., 2001; Eucker et al., 2002) . These results are consistent with the conclusion that inhibition of DNA repair processes with a nucleotide analog kills cells by mechanisms that are different from those by which these classes of drugs act individually.
Genetically defined cell lines have been employed to evaluate the signaling mechanisms related to the cell death associated with the inhibition of UV-induced DNA repair by fludarabine. Such treatment was associated with the phosphorylation of p53 on serine-15 and serine-37 in lymphocytes and various cell lines within 1 h after irradiation (Rao and Plunkett, 2002) . Phosphorylation of serine-15 of p53 inhibits the interaction of p53 with mdm2 in vitro. The mdm2 protein can inhibit the function of p53 as a transcription factor by binding to the p53 N-terminus, thereby preventing p53 from interacting with the transcriptional machinery and preventing the activation of p53-responsive genes (Momand et al., 1992; Chen et al., 1993) . Importantly, mouse embryo fibroblasts that lacked functional p53 displayed resistance to the actions of F-ara-A and UV (Rao and Plunkett, 2002) .
Members of the PI-3 kinase phosphorylate p53 and lead to its subsequent stabilization (Lees-Miller et al., 1995; Lakin and Jackson, 1999; Tibbetts et al., 1999; Shiloh, 2001) . In studies using fibroblasts from an ATM patient and a line that was established after repletion of normal ATM, loss in viability of quiescent cells treated with UV and F-ara-A was independent of ATM function (Rao and Plunkett, 2002) . Future studies should evaluate the potential participation of other members of the PI-3 kinase family, DNA-PK and ATR, to develop an understanding of how quiescent cells activate p53 in response to DNA repair inhibition.
The transcriptional activity of p53 is known to increase the expression of various proapoptotic genes including the Fas death receptor (Miyashita and Reed, 1995; Owen-Schaub et al., 1995; Muller et al., 1997; Kobayashi et al., 1998; Muller et al., 1998; Fukazawa et al., 1999) . Increased levels of Fas and Fas ligand transcripts and accumulation of the proteins have been observed following DNA repair inhibition by fludarabine (Rao and Plunkett, 2002) . This was associated with the activation of caspase-8, and also caspase-3. Finally, antibodies that were antagonistic to the receptor-ligand interaction significantly reduced the percentage of dying cells, implicating the Fas death receptor pathway as a means of executing apoptosis after inhibition of DNA repair. This is reminiscent of the pathway that is activated in growing cells by the treatment of colon cancer cells with fluorinated pyrimidines (Petak and Houghton, 2001 ) and of Tlymphoblast response to a purine nucleoside (Rodriguez et al., 2003) . In the future, it will be important to evaluate a potential link between the transcriptional activity of p53 and the expression of Fas receptor following DNA repair as this could provide a linkage to the extrinsic pathway of apoptosis.
Abbreviations ara-C, arabinosylcytosine; dNTP, deoxynucleotide triphosphate; DNA-PK, DNA-activated protein kinase; HU, hydroxyurea; JNK, c-jun-N-terminal kinase.
